277 related articles for article (PubMed ID: 36367020)
1. Cancer-cell-intrinsic mechanisms shaping the immunosuppressive landscape of prostate cancer.
Zhu Y; Duong L; Lu X; Lu X
Asian J Androl; 2023; 25(2):171-178. PubMed ID: 36367020
[TBL] [Abstract][Full Text] [Related]
2. Effective combinatorial immunotherapy for castration-resistant prostate cancer.
Lu X; Horner JW; Paul E; Shang X; Troncoso P; Deng P; Jiang S; Chang Q; Spring DJ; Sharma P; Zebala JA; Maeda DY; Wang YA; DePinho RA
Nature; 2017 Mar; 543(7647):728-732. PubMed ID: 28321130
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy in treatment of metastatic prostate cancer: An approach to circumvent immunosuppressive tumor microenvironment.
Sun BL
Prostate; 2021 Nov; 81(15):1125-1134. PubMed ID: 34435699
[TBL] [Abstract][Full Text] [Related]
4. Moving toward improved immune checkpoint immunotherapy for advanced prostate cancer.
De Velasco MA; Kura Y; Fujita K; Uemura H
Int J Urol; 2024 Apr; 31(4):307-324. PubMed ID: 38167824
[TBL] [Abstract][Full Text] [Related]
5. Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer.
Rathi N; McFarland TR; Nussenzveig R; Agarwal N; Swami U
Drugs; 2021 Feb; 81(2):191-206. PubMed ID: 33369720
[TBL] [Abstract][Full Text] [Related]
6. Prostate Cancer Immunotherapy-Finally in From the Cold?
Runcie KD; Dallos MC
Curr Oncol Rep; 2021 Jun; 23(8):88. PubMed ID: 34125308
[TBL] [Abstract][Full Text] [Related]
7. Targeting the chromatin effector Pygo2 promotes cytotoxic T cell responses and overcomes immunotherapy resistance in prostate cancer.
Zhu Y; Zhao Y; Wen J; Liu S; Huang T; Hatial I; Peng X; Al Janabi H; Huang G; Mittlesteadt J; Cheng M; Bhardwaj A; Ashfeld BL; Kao KR; Maeda DY; Dai X; Wiest O; Blagg BSJ; Lu X; Cheng L; Wan J; Lu X
Sci Immunol; 2023 Mar; 8(81):eade4656. PubMed ID: 36897957
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer immunotherapy: where are we and where are we going?
De Velasco MA; Uemura H
Curr Opin Urol; 2018 Jan; 28(1):15-24. PubMed ID: 29095729
[TBL] [Abstract][Full Text] [Related]
9. Beyond immune checkpoint blockade: new approaches to targeting host-tumor interactions in prostate cancer: report from the 2014 Coffey-Holden prostate cancer academy meeting.
Miyahira AK; Kissick HT; Bishop JL; Takeda DY; Barbieri CE; Simons JW; Pienta KJ; Soule HR
Prostate; 2015 Mar; 75(4):337-47. PubMed ID: 25358693
[TBL] [Abstract][Full Text] [Related]
10. Immunological Complexity of the Prostate Cancer Microenvironment Influences the Response to Immunotherapy.
Prokhnevska N; Emerson DA; Kissick HT; Redmond WL
Adv Exp Med Biol; 2019; 1210():121-147. PubMed ID: 31900908
[TBL] [Abstract][Full Text] [Related]
11. How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer.
Stultz J; Fong L
Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):697-717. PubMed ID: 33820953
[TBL] [Abstract][Full Text] [Related]
12. Non-coding RNAs: Emerging roles in the characterization of immune microenvironment and immunotherapy of prostate cancer.
Yang F; Li J; Ge Q; Zhang Y; Zhang M; Zhou J; Wang H; Du J; Gao S; Liang C; Meng J
Biochem Pharmacol; 2023 Aug; 214():115669. PubMed ID: 37364622
[TBL] [Abstract][Full Text] [Related]
13. The Immunotherapy and Immunosuppressive Signaling in Therapy-Resistant Prostate Cancer.
Xu P; Wasielewski LJ; Yang JC; Cai D; Evans CP; Murphy WJ; Liu C
Biomedicines; 2022 Jul; 10(8):. PubMed ID: 35892678
[TBL] [Abstract][Full Text] [Related]
14. Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy.
Ma Z; Zhang W; Dong B; Xin Z; Ji Y; Su R; Shen K; Pan J; Wang Q; Xue W
Theranostics; 2022; 12(11):4965-4979. PubMed ID: 35836810
[No Abstract] [Full Text] [Related]
15. The evolving landscape of immunotherapy in advanced prostate cancer.
Patel VG; Oh WK
Immunotherapy; 2019 Jul; 11(10):903-912. PubMed ID: 31161846
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy in Advanced Prostate Cancer-Light at the End of the Tunnel?
von Amsberg G; Alsdorf W; Karagiannis P; Coym A; Kaune M; Werner S; Graefen M; Bokemeyer C; Merkens L; Dyshlovoy SA
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269712
[TBL] [Abstract][Full Text] [Related]
17. The requirement for immune infiltration and organization in the tumor microenvironment for successful immunotherapy in prostate cancer.
Jansen CS; Prokhnevska N; Kissick HT
Urol Oncol; 2019 Aug; 37(8):543-555. PubMed ID: 30446449
[TBL] [Abstract][Full Text] [Related]
18. The tumor microenvironment and immune responses in prostate cancer patients.
Kwon JTW; Bryant RJ; Parkes EE
Endocr Relat Cancer; 2021 Jul; 28(8):T95-T107. PubMed ID: 34128831
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy for Metastatic Prostate Cancer: Current and Emerging Treatment Options.
Chakravarty D; Huang L; Kahn M; Tewari AK
Urol Clin North Am; 2020 Nov; 47(4):487-510. PubMed ID: 33008499
[TBL] [Abstract][Full Text] [Related]
20. Overcoming Immune Resistance With Radiation Therapy in Prostate Cancer.
Mulvey A; Muggeo-Bertin E; Berthold DR; Herrera FG
Front Immunol; 2022; 13():859785. PubMed ID: 35603186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
